透析前期慢性肾脏病患者支持性照护应用程序的构建及初步应用

注册号:

Registration number:

ChiCTR2500103792 

最近更新日期:

Date of Last Refreshed on:

2025-06-05 15:11:50 

注册时间:

Date of Registration:

2025-06-05 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

透析前期慢性肾脏病患者支持性照护应用程序的构建及初步应用

Public title:

Development and Preliminary Application of a Supportive Care Application for Patients with Pre-dialysis Chronic Kidney Disease

注册题目简写:

English Acronym:

研究课题的正式科学名称:

透析前期慢性肾脏病患者支持性照护应用程序的构建及初步应用

Scientific title:

Development and Preliminary Application of a Supportive Care Application for Patients with Pre-dialysis Chronic Kidney Disease

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

胡锦 

研究负责人:

胡锦;莫永珍 

Applicant:

Jin Hu 

Study leader:

Jin Hu;Yongzhen Mo 

申请注册联系人电话:

Applicant telephone:

+86 188 0065 1131

研究负责人电话:

Study leader's
telephone:

+86 188 0065 1131

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

798034574@qq.com

研究负责人电子邮件:

Study leader's E-mail:

798034574@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

江苏省南京市鼓楼区马台街70号2号楼宜城公寓(中大医院店)

研究负责人通讯地址:

江苏省南京市鼓楼区马台街70号2号楼宜城公寓(中大医院店)

Applicant address:

Building 2, Yicheng Apartment (Zhongda Hospital Branch), No. 70 Matai Street, Gulou District, Nanjing, Jiangsu Province, China

Study leader's address:

Building 2, Yicheng Apartment (Zhongda Hospital Branch), No. 70 Matai Street, Gulou District, Nanjing, Jiangsu Province, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

江苏省省级机关医院

Applicant's institution:

Jiangsu Province Official Hospita

研究负责人所在单位:

江苏省省级机关医院

Affiliation of the Leader:

Jiangsu Province Official Hospita

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

(2025)院伦意见第051-1号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

江苏省省级机关医院伦理审查委员会

Name of the ethic committee:

Ethics Committee of Jiangsu Province Official Hospita

伦理委员会批准日期:

Date of approved by ethic committee:

2025-05-27 00:00:00

伦理委员会联系人:

黄健

Contact Name of the ethic committee:

Jian Huang

伦理委员会联系地址:

南京市珞珈路30号

Contact Address of the ethic committee:

No. 30 Luojia Road, Nanjing, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 138 5167 2889

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

江苏省省级机关医院

Primary sponsor:

Jiangsu Province Official Hospita

研究实施负责(组长)单位地址:

南京市江苏路65号

Primary sponsor's address:

No. 65 Jiangsu Road, Nanjing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏

市(区县):

Country:

China

Province:

Jiangsu

City:

单位(医院):

江苏省省级机关医院

具体地址:

南京市江苏路65号

Institution
hospital:

Jiangsu Province Official Hospita

Address:

No. 65 Jiangsu Road, Nanjing, China

经费或物资来源:

自筹经费

Source(s) of funding:

Self-funded

研究疾病:

慢性肾脏病  

Target disease:

Chronic Kidney Disease

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

非随机对照试验 

Study design:

Non randomized control 

研究目的:

构建一款适用于透析前期患者的移动医疗应用程序,并在实际临床环境中进行初步应用。研究将评估该应用程序在改善患者生活质量、缓解焦虑和抑郁状态、提升患者激活水平方面的初步效果。  

Objectives of Study:

This study aims to construct a mobile health application designed for patients in the pre-dialysis phase and to conduct a preliminary application in clinical practice. The effectiveness of the application will be initially evaluated in terms of improving quality of life, reducing anxiety and depression, and enhancing patient activation.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.准备接受肾移植治疗; 2.急性肾衰竭的患者; 3.合并严重其他疾病,如恶性肿瘤; 4. 正在参与干预性临床试验。

Exclusion criteria:

1.Planned to undergo kidney transplantation; 2.Diagnosed with acute kidney failure; 3.Presence of severe comorbid conditions, such as malignant tumors; 4.Currently participating in another interventional clinical trial.

研究实施时间:

Study execute time:

From 2025-06-15 00:00:00 To 2026-05-26 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-07-01 00:00:00 To 2025-12-01 00:00:00

干预措施:

Interventions:

组别:

对照组

样本量:

26

Group:

Control group

Sample size:

干预措施:

常规干预,包括根据病情定期前往医院就诊,规律使用医嘱药物,接受生活方式指导及健康教育咨询,并在医护人员指导下开展饮食控制、适度运动等自我管理措施。此外,还将获得纸质形式的健康宣教材料,用于日常参考与学习。

干预措施代码:

Intervention:

Conventional intervention includes regular hospital visits based on the patient's condition, adherence to prescribed medications, and receiving lifestyle guidance and health education counseling. Patients are also encouraged to engage in self-management activities such as dietary control and moderate physical exercise under the guidance of healthcare professionals. In addition, participants will receive printed health education materials for daily reference and learning.

Intervention code:

组别:

干预组

样本量:

26

Group:

Intervention group

Sample size:

干预措施:

使用健康管理APP进行自我管理

干预措施代码:

Intervention:

Self-management using a health management application

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏 

市(区县):

 

Country:

China

Province:

Jiangsu

City:

单位(医院):

江苏省省级机关医院 

单位级别:

三级 

Institution
hospital:

Jiangsu Province Official Hospita

Level of the institution:

Tertiary

测量指标:

Outcomes:

指标中文名:

生活质量

指标类型:

主要指标

Outcome:

Quality of Life

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

焦虑状态

指标类型:

次要指标

Outcome:

Anxiety status

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

抑郁状态

指标类型:

次要指标

Outcome:

Depression status

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

患者激活

指标类型:

次要指标

Outcome:

Patient activation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

系统可用性

指标类型:

次要指标

Outcome:

System usability

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 85 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

参与者按先后顺序入组,先入组者分配到对照组,后入组者分配到干预组。

Randomization Procedure (please state who generates the random number sequence and by what method):

Participants were assigned sequentially: those who enrolled first were allocated to the control group, and subsequent participants were assigned to the intervention group.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

电子采集和管理

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Electronic Data Capture

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-06-05 15:11:39